Nowadays, the growth of the urogenital infections frequency could be visible because of the introduction of the screening programs and utilization of the high-sensitive diagnostic methods and also because of the full registration of the primary cases.

Clinical significance of the sexuallytransmitted diseases (STD) in young men is a consequence of the high transmission and acquisition risks of HIV-infection and the possibility of the development of the chronic diseases of genitalia, complicated in some cases by infertility. Modern antibiotics therapy, which is effective against the atypical intracellular microorganisms – causative agents of the non-gonococci urethritis – is performed using the medications groups of macrolides, tetracyclines and fluoroquinolones. Nitroimidazoles are still the only group for treatment of the patients with trichomoniasis. Of special interest is now a combination medication for mixed infection, which recently entered the market, Combyflox®, the combination of the ofloxacin 200 mg and ornidazole 500 mg in one tablet. This new drug has a number of merits: a high activity against Chlamydia, Mycoplasma and Trichomonas, ability to create high and stable concentrations in the tissues, long half-life period and good tolerance profile. These merits make this medication a good alternative for treatment of men with STD.